SLC5A2 and hydrops fetalis: Although previous studies have demonstrated the significant efficacy of SGLT2 inhibitors in improving left ventricular remodeling and systolic function among HF patients, there is a paucity of clinical research investigating the application of these inhibitors in individuals with NIDCM.